Nurix Therapeutics, Inc. (NRIX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Core Insights - Nurix Therapeutics is advancing its Phase III trial design for its lead program, bexobrutideg, which represents a new class of therapeutics known as targeted protein degraders [2][3][4] - The company positions bexobrutideg as the first drug in this new mechanism of action (MOA), indicating its potential significance in the evolution of therapeutic options [3][4] Company Overview - Arthur Sands serves as the President and CEO of Nurix Therapeutics, leading the discussion on the company's innovative approaches [1][3] - The company emphasizes the transition from traditional therapies, such as small molecule inhibitors and antibodies, to a novel class of drugs that utilize targeted protein degradation [3][4]